KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Non-Current Deffered Revenue: 2009-2012

Historic Non-Current Deffered Revenue for Acadia Pharmaceuticals (ACAD) over the last 3 years, with Jun 2012 value amounting to $2.4 million.

  • Acadia Pharmaceuticals' Non-Current Deffered Revenue fell 3.02% to $2.4 million in Q2 2012 from the same period last year, while for Jun 2012 it was $2.4 million, marking a year-over-year decrease of 3.02%. This contributed to the annual value of $2.6 million for FY2011, which is 1.37% down from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Non-Current Deffered Revenue of $2.4 million as of Q2 2012, which was down 3.80% from $2.5 million recorded in Q1 2012.
  • Acadia Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $23.9 million for Q3 2009, and its period low was $2.4 million during Q2 2012.
  • For the 3-year period, Acadia Pharmaceuticals' Non-Current Deffered Revenue averaged around $8.5 million, with its median value being $2.6 million (2011).
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Non-Current Deffered Revenue increased by 2.53% in 2010, and later tumbled by 89.20% in 2011.
  • Acadia Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $22.6 million in 2009, then slumped by 88.38% to $2.6 million in 2010, then declined by 1.37% to $2.6 million in 2011, then declined by 3.02% to $2.4 million in 2012.
  • Its last three reported values are $2.4 million in Q2 2012, $2.5 million for Q1 2012, and $2.6 million during Q4 2011.